MAPT and Alzheimer disease: A panel of fluid biomarkers (cerebrospinal fluid [CSF] and plasma) was performed every 30 days, providing a comprehensive battery of noninvasive markers of neurodegeneration and neuroinflammation in a novel tau monkey model that recapitulates key features of tau pathology propagation in AD.